EBA
YMAB

Eagle Bay Advisors’s Y-mAbs Therapeutics YMAB Stock Holding History

Eagle Bay Advisors’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50
Closed -$392 – 967
2024
Q4 		$392 Hold
50
– – ﹤0.01% 971
2024
Q3 		$658 Hold
50
– – ﹤0.01% 1305
2024
Q2 		$604 Hold
50
– – ﹤0.01% 955
2024
Q1 		$813 Hold
50
– – ﹤0.01% 932
2023
Q4 		$341 Hold
50
– – ﹤0.01% 805
2023
Q3 		$273 Hold
50
– – ﹤0.01% 828
2023
Q2 		$340 Hold
50
– – ﹤0.01% 819
2023
Q1 		$251 Hold
50
– – ﹤0.01% 892
2022
Q4 		$244 Hold
50
– – ﹤0.01% 906
2022
Q3 		$1K Hold
50
– – ﹤0.01% 886
2022
Q2 		$757 Buy
+50
New +$583 ﹤0.01% 951
2022
Q1 		– Sell
-50
Closed -$1K – 996
2021
Q4 		$1K Hold
50
– – ﹤0.01% 1071
2021
Q3 		$1K Buy
+50
New +$1.58K ﹤0.01% 1068

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Eagle Bay Advisors's YMAB Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 50 shares — an estimated $392 sold.

Eagle Bay Advisors first reported a position in YMAB in Q3 2021 and held it in 13 quarters. The position peaked at $1K in Q3 2022. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 50 Y-mAbs Therapeutics shares in Q1 2025, an estimated $392.
  • Eagle Bay Advisors first reported a position in Y-mAbs Therapeutics in Q3 2021 and held it in 13 quarters.
  • Eagle Bay Advisors's Y-mAbs Therapeutics position peaked at $1K in Q3 2022.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.